This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…
Phase: PHASE1 • Sponsor: OnKure, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC